Live price temporarily unavailable.
Corcept Therapeutics (CORT) is a Health Care company in the Russell 1000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $81.3M | $159.2M | $251.2M | $306.5M | $353.9M | $366.0M | $401.9M | $482.4M | $675.0M | $761.4M |
| Growth (year over year) | +61.7% | +95.8% | +57.8% | +22.0% | +15.5% | +3.4% | +9.8% | +20.0% | +39.9% | +12.8% |
| Gross profit | $79.3M | $155.6M | $246.0M | $301.0M | $348.3M | $360.7M | $396.5M | $475.9M | $664.2M | $748.4M |
| Gross margin | 97.5% | 97.8% | 97.9% | 98.2% | 98.4% | 98.6% | 98.7% | 98.7% | 98.4% | 98.3% |
| Operating income | $10.2M | $52.9M | $89.5M | $111.6M | $128.2M | $124.5M | $112.6M | $107.3M | $137.0M | $44.8M |
| Operating margin | 12.5% | 33.2% | 35.6% | 36.4% | 36.2% | 34.0% | 28.0% | 22.2% | 20.3% | 5.9% |
| Net income | $8.14M | $129.1M | $75.4M | $94.2M | $106.0M | $112.5M | $101.4M | $106.1M | $141.2M | $99.7M |
| Net margin | 10.0% | 81.1% | 30.0% | 30.7% | 30.0% | 30.7% | 25.2% | 22.0% | 20.9% | 13.1% |
| EPS (diluted) | $0.07 | $1.04 | $0.60 | $0.77 | $0.85 | $0.89 | $0.87 | $0.94 | $1.23 | $0.82 |
| Balance sheet | ||||||||||
| Cash and equivalents | $51.5M | $31.1M | $41.6M | $31.3M | $76.2M | $77.6M | $66.3M | $135.6M | $127.7M | $120.5M |
| Total assets | $68.8M | $220.5M | $311.7M | $412.3M | $571.7M | $423.8M | $583.4M | $621.5M | $840.6M | $836.7M |
| Total liabilities | $27.4M | $29.6M | $35.8M | $41.1M | $48.4M | $48.0M | $81.6M | $114.8M | $161.0M | $188.8M |
| Long-term debt | $0 | $0 | — | — | — | — | — | — | — | — |
| Shareholders' equity | $41.4M | $191.0M | $275.9M | $371.2M | $523.3M | $375.8M | $501.8M | $506.7M | $679.6M | $647.8M |
| Cash flow | ||||||||||
| Operating cash flow | $18.4M | $60.9M | $115.7M | $136.1M | $152.0M | $167.9M | $120.3M | $126.7M | $198.3M | $142.0M |
| Capital expenditure | $194.0K | $419.0K | $298.0K | $1.09M | $1.24M | $469.0K | $413.0K | $139.0K | $2.17M | $211.0K |
| Free cash flow | $18.2M | $60.5M | $115.4M | $135.0M | $150.7M | $167.4M | $119.9M | $126.5M | $196.1M | $141.8M |
| Share buybacks | $0 | $0 | $23.7M | $31.0M | $9.95M | — | $0 | $0 | $15.7M | $172.9M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $182.5M | $181.9M | $157.2M | $194.4M | $207.6M | $202.1M | $164.9M | $256.1M |
| Growth (year over year) | +47.7% | +34.3% | +7.1% | +18.7% | +13.7% | +11.1% | +4.9% | +31.7% |
| Gross profit | $179.7M | $178.9M | $154.8M | $191.0M | $203.0M | $199.6M | $162.0M | $252.1M |
| Gross margin | 98.4% | 98.4% | 98.5% | 98.2% | 97.8% | 98.7% | 98.3% | 98.4% |
| Operating income | $46.6M | $25.3M | $3.42M | $26.7M | $10.2M | $4.49M | −$49.6M | $41.3M |
| Operating margin | 25.5% | 13.9% | 2.2% | 13.7% | 4.9% | 2.2% | −30.1% | 16.1% |
| Net income | $47.2M | $30.7M | $20.5M | $35.1M | $19.7M | $24.3M | −$31.8M | $43.0M |
| Net margin | 25.9% | 16.9% | 13.1% | 18.1% | 9.5% | 12.0% | −19.3% | 16.8% |
| EPS (diluted) | $0.41 | $0.25 | $0.17 | $0.29 | $0.16 | $0.20 | −$0.30 | $0.36 |
| Balance sheet | ||||||||
| Cash and equivalents | $137.3M | $127.7M | $89.8M | $102.7M | $125.1M | $120.5M | $108.7M | $111.0M |
| Total assets | $784.3M | $840.6M | $846.5M | $801.7M | $823.6M | $836.7M | $814.9M | $888.7M |
| Total liabilities | $145.4M | $161.0M | $163.2M | $165.9M | $191.7M | $188.8M | $176.9M | $182.9M |
| Shareholders' equity | $638.8M | $679.6M | $683.3M | $635.8M | $631.9M | $647.8M | $638.0M | $705.8M |
| Cash flow | ||||||||
| Operating cash flow | $73.3M | $60.1M | $4.77M | $44.3M | $54.5M | $38.4M | −$16.8M | $33.5M |
| Capital expenditure | $1.64M | $121.0K | $104.0K | $57.0K | $0 | $50.0K | $201.0K | $2.53M |
| Free cash flow | $71.7M | $59.9M | $4.67M | $44.2M | $54.5M | $38.4M | −$17.0M | $31.0M |
| Share buybacks | $11.7M | $0 | $27.4M | $103.0M | $42.5M | $0 | $0 | $0 |
From Corcept Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.
Source: Wikipedia — Corcept Therapeutics
No recent news mentioning Corcept Therapeutics in our feed yet.